* Core Laboratories Inc CLB.N CLB is expected to show a
rise
in quarterly revenue when it reports results on November 1.
* The Houston Texas-based company is expected to report a
3.2% increase in revenue to $129.975 million from $125.97
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. The company's guidance on
July 26 2023, for the period ended September 30, was for revenue
between $128.00 million and $132.00 million.
* Refinitiv's mean analyst estimate for Core Laboratories
Inc is
for earnings of 22 cents per share. The company's EPS guidance
on July 26 2023, for the period ended September 30, was between
$0.21 and $0.25
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 6
"hold" and 2 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Core
Laboratories
Inc is $21.5, below its last closing price of $21.52.
The company's guidance on July 26 2023 for the period ended
September 30 was for Earnings before Interest and Taxes between
USD15.2 million and USD17.5 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2023 0.20 0.20 0.21 Beat 5.3
Mar. 31 2023 0.16 0.16 0.19 Beat 20.3
Dec. 31 2022 0.19 0.20 0.20 Met 2.2
Sep. 30 2022 0.15 0.15 0.18 Beat 20.3
Jun. 0.12 0.14 0.12 Missed -12
30 2022
Mar. 31 2022 0.07 0.09 0.08 Missed -11.6
Dec. 31 2021 0.20 0.20 0.20 Met -0.4
Sep. 30 2021 0.18 0.19 0.18 Missed -3.8
This summary was machine generated October 31 at 02:04 GMT. All
figures in US dollars unless otherwise stated